# ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

> **NCT07497594** · NA · RECRUITING · sponsor: **Oswaldo Cruz Foundation** · enrollment: 1500 (estimated)

## Conditions studied

- Contact With or Exposure to Human Immunodeficiency Virus

## Interventions

- **DRUG:** Lenacapavir long-acting
- **DRUG:** Tenofovi-Emtricitabine (TDF/FTC) tablet

## Key facts

- **NCT ID:** NCT07497594
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2029-02
- **Final completion:** 2029-09
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497594, "ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07497594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*